The sulphonylurea receptor (SUR) subunits of KATP channels are the targets for several
classes of therapeutic drugs. Sulphonylureas close KATP channels in pancreatic β-cells and …

Sulfonylureas stimulate insulin secretion in type-2 diabetic patients by blocking ATP-
sensitive (KATP) potassium channels in the pancreatic β-cell membrane. This effect is …

Sulfonylureas are widely used to treat type 2 diabetes because they stimulate insulin
secretion from pancreatic β-cells. They primarily act by binding to the SUR subunit of the …

Insulin secretagogues (sulfonylureas and glinides) increase insulin secretion by closing the
ATP-sensitive K+ channel (KATP channel) in the pancreatic β-cell membrane. KATP …

Sulphonylureas have been used for over 50 years to enhance insulin secretion in patients
with Type II (non-insulin-dependent) diabetes mellitus but their therapeutic target was not …

Sulfonylureas are widely used to stimulate insulin secretion in type 2 diabetic patients
because they close adenosine triphosphate-sensitive potassium (KATP) channels in the …

ATP-sensitive K+ (KATP) channels play many important roles in cellular functions, including
control of membrane excitability of skeletal muscle and neurons, K+ recycling in renal …

Repaglinide and nateglinide represent a new class of insulin secretagogues, structurally
unrelated to sulphonylureas, that were developed for the treatment of type 2 diabetes. The …

Hypoglycaemic agents such as sulphonylureas and the newer group of" glinides" stimulate
insulin secretion by closing ATP-sensitive potassium (K ATP) channels in pancreatic beta …

Aims/hypothesis: Sulphonylureas stimulate insulin secretion by closing ATP-sensitive
potassium (K ATP) channels in the pancreatic beta-cell membrane. K ATP channels are also …